<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129272</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-15131-1</org_study_id>
    <nct_id>NCT00129272</nct_id>
  </id_info>
  <brief_title>Effectiveness of Bupropion for Treating Nicotine Dependence in Young People</brief_title>
  <official_title>Stress Response and Smoking Cessation in Depressed Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about the best ways to help young people stop smoking. Bupropion (a
      medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers. The
      purpose of this study is to determine if bupropion is also effective in treating smokers
      between the ages of 12 and 25 years old. This study also compares the effectiveness of
      bupropion used as a supplement to behavioral treatment versus behavioral treatment used
      alone. In addition, the study evaluates whether hormonal response to stress measured prior to
      the start of treatment predicts whether individuals respond well to treatment with
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking and other forms of tobacco exposure are one of the leading preventable
      causes of morbidity and mortality in the United States. Most smokers begin smoking during
      adolescence, and though they seem motivated to quit smoking, they frequently fail. Although
      behavioral treatments are available, they have not been very successful in past studies.

      Depressed adults may have more difficulty quitting smoking than non depressed adults; this
      finding may also apply to depressed youth. The purpose of this study is to determine the
      effectiveness of bupropion in combination with standard behavioral treatment in helping young
      smokers quit, as compared to behavioral treatment alone. Finally, the study examines whether
      hormonal response to stress measured prior to treatment initiation predicts whether
      individuals respond well to treatment with bupropion.

      Participants in this double-blind study will be randomly assigned to receive either bupropion
      or placebo. Both groups will receive behavioral treatment. The trial will last for 9 weeks,
      with weekly study visits. Study visits will last 30 minutes to 1 hour and will include
      medication monitoring, self-reported and biological measures of smoking, and behavioral
      treatment. Participants will have follow-up visits six months after completion of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking Behavior</measure>
    <time_frame>Nine weeks</time_frame>
    <description>Number of cigarettes smoked daily in the previous week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Withdrawal Symptoms</measure>
    <time_frame>Nine weeks</time_frame>
    <description>Hughes-Hatsukami Withdrawal Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Tobacco Use Cessation</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Bupropion (Wellbutrin-SR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion-SR</intervention_name>
    <description>150mg tablets taken orally twice daily for 9 weeks.</description>
    <arm_group_label>Bupropion (Wellbutrin-SR)</arm_group_label>
    <other_name>Wellbutrin-SR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (to Buproion-SR) twice daily for 9 weeks.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <other_name>Placebo match for Bupropion (Wellbutrin) SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has smoked at least 10 cigarettes each day for 3 or more months

          -  Weighs at least 90 lbs

          -  Motivated to quit smoking and has had at least one previous failed attempt

          -  Speaks, reads, and writes English

          -  Either diagnosed as depressed OR no history of a psychiatric disorder

        Exclusion Criteria:

          -  History of bipolar disorder, eating disorder, schizophrenia, schizoaffective disorder,
             autism, or non-nicotine substance use disorder in the 6 months prior to study entry

          -  Currently suicidal or with a history of a suicide attempt in the 6 months prior to
             study entry

          -  Psychotic symptoms

          -  Use of psychotropic medication(s)

          -  Serious medical condition

          -  Prior use of bupropion for smoking cessation

          -  Currently using other smoking cessation treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uma Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390 9101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <results_first_submitted>January 16, 2017</results_first_submitted>
  <results_first_submitted_qc>March 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Drug Abuse (NIDA)</investigator_affiliation>
    <investigator_full_name>Uma Rao</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>adolescents, cigarettes, smoking, tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants between ages 12 and 25 years who smoked at least 10 cigarettes per day over a period of 6 months were recruited between 2004 and 2010 through advertisements in local newspapers and flyers in local community agencies and primary care clinics.</recruitment_details>
      <pre_assignment_details>Participants completed an assessment for nicotine dependence and psychiatric disorders, and a laboratory stress study to assess baseline salivary cortisol over 2 hours and cortisol responses to a psychosocial stressor (public speaking and arithmetic tasks). Those who continued to meet study criteria were then randomized to active drug or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug (Burpropion-SR)</title>
          <description>In total 172 participants were recruited, and 144 were randomized.
Using a double-blind, randomized, placebo-controlled design, participants were randomized to active drug or placebo using the modified Efronâ€™s biased coin toss method to ensure that the drug/placebo cells are balanced with respect to severe depression, presence of nicotine dependence symptoms and gender.
Participants received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
The participants had weekly visits with the target quitting date set for Day 8. The medication checks lasted about 30-45 minutes. The focus was on elicitation of smoking status, nicotine craving and withdrawal symptoms, depressive symptoms and side effects. Body weight and vital signs were measured as well as expired air for CO and urine cotinine levels. Plasma drug levels were obtained at 5 and 9 weeks of treatment.</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo</title>
          <description>This arm included placebo treatment twice daily for 9 weeks. Drug and placebo were compounded to look identical, masking both drug type and dosage.
All participants (both drug and placebo groups) received a modified version of the brief office intervention program for adolescent smokers, developed by the American Medical Association. Subjects met with a research counselor for 10 consecutive weekly sessions. The initial session (baseline visit) was 60 min. while the remaining sessions were 20-30 min. Each session was individualized to the needs of the adolescent, based on information gathered at the baseline assessment. The brief office intervention materials include checklists and guidelines for each session to assist the counselor in tailoring the session to the needs of the youth. It involved motivational interviewing, incorporating stages of change, peer and parental and other social influences; negative affect and other psychological factors, addiction and self-efficacy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug (Bupropion-SR)</title>
          <description>Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-Sr (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Bupropion-SR: 150mg tablets taken orally twice daily for 9 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Matching Placebo</title>
          <description>Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Placebo: Matching placebo (to Buproion-SR) twice daily for 9 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Participants were between 12 and 25 years of age.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="3.2"/>
                    <measurement group_id="B2" value="18.3" spread="3.9"/>
                    <measurement group_id="B3" value="19.0" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black : non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black : Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White : non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White : Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race : non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race : Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>The data were collected in Southwestern Region of the United States</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily smoking diary</title>
          <description>Number of cigarettes smoked per day</description>
          <units>cigarettes/day in previous week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" spread="7.6"/>
                    <measurement group_id="B2" value="16.4" spread="6.8"/>
                    <measurement group_id="B3" value="16.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Withdrawal symptoms</title>
          <description>Hughes-Hatsukami Withdrawal Scale</description>
          <units>units on a scale;range 0-36;higher worse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="3.3"/>
                    <measurement group_id="B2" value="4.1" spread="3.5"/>
                    <measurement group_id="B3" value="4.2" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nicotine dependence</title>
          <description>Fagerstrom Tolerance Questionnaire</description>
          <units>units on a scale;range 0-9;higher worse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="1.6"/>
                    <measurement group_id="B2" value="5.4" spread="1.3"/>
                    <measurement group_id="B3" value="5.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expired carbon monoxide</title>
          <units>Parts per million; higher worse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="5.3"/>
                    <measurement group_id="B2" value="14.0" spread="8.9"/>
                    <measurement group_id="B3" value="13.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Smoking Behavior</title>
        <description>Number of cigarettes smoked daily in the previous week</description>
        <time_frame>Nine weeks</time_frame>
        <population>Analyzed all randomized participants with last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Bupropion-SR)</title>
            <description>Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-Sr (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Bupropion-SR: 150mg tablets taken orally twice daily for 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Placebo: Matching placebo (to Buproion-SR) twice daily for 9 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Behavior</title>
          <description>Number of cigarettes smoked daily in the previous week</description>
          <population>Analyzed all randomized participants with last observation carried forward (LOCF).</population>
          <units>cigarettes/day in the previous week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="4.3"/>
                    <measurement group_id="O2" value="8.9" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal Symptoms</title>
        <description>Hughes-Hatsukami Withdrawal Scale</description>
        <time_frame>Nine weeks</time_frame>
        <population>Analyzed all participants with last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Bupropion-SR)</title>
            <description>Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-Sr (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Bupropion-SR: 150mg tablets taken orally twice daily for 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Placebo: Matching placebo (to Buproion-SR) twice daily for 9 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal Symptoms</title>
          <description>Hughes-Hatsukami Withdrawal Scale</description>
          <population>Analyzed all participants with last observation carried forward (LOCF).</population>
          <units>units on a scale;range0-36;higher worse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.3"/>
                    <measurement group_id="O2" value="3.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time frame for adverse events was over 9 weeks of treatment.</time_frame>
      <desc>Adverse events were recorded based on Hughes-Hatsukami Withdrawal Scale and Side Effects Form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Drug (Bupropion-SR)</title>
          <description>Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-Sr (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Bupropion-SR: 150mg tablets taken orally twice daily for 9 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo</title>
          <description>Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
Placebo: Matching placebo (to Buproion-SR) twice daily for 9 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Negative affect</sub_title>
                <description>negative mood/affect reported during the course of treatment</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" events="23" subjects_affected="8" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Uma Rao, MD</name_or_title>
      <organization>The University of Tennessee</organization>
      <phone>615-794-3351</phone>
      <email>urao@utk.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

